[1] Jung KY, Cho SY, Kim HJ, et al.Nonalcoholic steatohepatitis associated with metabolic syndrome: relationship to insulin resistance and liver histology. J Clin Gastroenterol, 2014,48:883-888.
[2] Shen F, Fan J. Progress in the study of nonalcoholic fatty liver disease: insights from research in 2013. Zhonghua Gan Zang Bing Za Zhi,2014 ,22:178-180.
[3] Tandon RK.Emergence of non-alcoholic fatty liver disease (NAFLD). J Assoc Physicians India,2013 ,61:445-446.
[4] 刘江奎,沈毅慧,刘翔川,等.替米沙坦对非酒精性脂肪性肝炎大鼠肝纤维化基质金属蛋白酶-13及其抑制因子-1的表达和胰岛素抵抗的影响.中华老年多器官疾病杂志,2011,10:357-361.
[5] 中华医学会肝病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪肝性肝病诊疗指南.中华肝脏病杂志,2010,18:161-166.
[6] 古赛,黄秒兴,吕发金,等.强肝胶囊治疗非酒精性脂肪性肝纤维化的临床研究.中西医结合肝病杂志,2011,21:68-70.
[7] Fassio E,Alvarez E,Dominquez N,et al. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies.Hepatology,2004,40:820-826.
[8] Matteoni CA,Younossi ZM,Gramlich T,et al. Nonalcoholic fatty liver disease:a spectrum of clinical and pathological severity.Gastroenterology,1999,116:1413-1419.
[9] Kuwashiro SI, Terai S, Oishi T, et al. Telmisartan improves nonalcoholic steatohepatitis in medaka (Oryzias latipes) by reducing macrophage infiltration and fat accumulation. Cell Tissue Res, 2011, 344:125-134.
[10] Nakagami H, Kiomy Osako M, Nakagami F, et al. Prevention and regression of non-alcoholic steatohepatitis (NASH) in a rat model by metabosartan,telmisartan. Int J Mol Med. 2010,26:477-481.
[11] Nakagami H, Morishita R.Obesity and gastrointestinal hormones-dual effect of angiotensin II receptor blockade and a partial agonist of PPAR-γ. Curr Vasc Pharmacol. 2011, 9: 162-166.
[12] Ueki M1, Koda M, Yamamoto S,et al. Preventive and therapeutic effects of angiotensin II type 1 receptor blocker on hepatic fibrosis induced by bile duct ligation in rats. J Gastroenterol,2006,41: 996-1004.
[13] Nakagami H, Kiomy Osako M, Nakagami F,et al.Prevention and regression of non-alcoholic steatohepatitis (NASH) in a rat model bymetabosartan, telmisartan. Int J Mol Med, 2010, 26: 477-481. |
